Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1999-07-26
2000-11-21
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
A61K 3800
Patent
active
061503339
ABSTRACT:
The present invention is directed to a method of treating one or more of the following disease and/or conditions, which comprises administering to a patient in need thereof the compound H-.beta.-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH.sub.2, where the Cysteines are bonded by a disulfide bond, or a pharmaceutically acceptable salt thereof, most preferably the acetate salt of the compound, in the treatment of certain diseases and/or conditions such as gastroenterological conditions and/or diseases, endocrinological diseases and/or conditions, various types of cancers and conditions associated with cancer such as cancer cachexia and in the treatment of hypotension and panic attacks.
REFERENCES:
patent: 4853371 (1989-08-01), Coy et al.
patent: 5073541 (1991-12-01), Taylor et al.
patent: 5147856 (1992-09-01), Ramwell et al.
patent: 5411943 (1995-05-01), Bogden
patent: 5504069 (1996-04-01), Bogden et al.
patent: 5686418 (1997-11-01), Culler
Anthony et al.,"Case Report: Lanreotide in the Management of Hypercalcemia of Malignancy," American Journal of the Medical Sciences, vol. 309, No. 6, Jun. 1995, pp. 312-314.
Kirk et al., "Somatostatin analogue in short term management of hyperinsulinism",Archives of Disease in Childhood,vol. 63, No. 12, 1988, pp. 1493-1494.
Khoo et al., "Palliation of malignant intestinal obstruction using ocreotide," Eurpoean Journal of Cancer,vol. 30A, No. 1, 1994,pp. 28-30.
Lamrani et al., "Effects of lanreotide, a somatostatin. . . secretions in humans," British Journal of Clinical Pharmacology,vol. 43, No. 1, 1997, pp. 65-70.
Clark, R.V., Clin. Res, vol. 38, No. 4, p. 943A, 1990.
Ambrosi, B., Acta Endocrinologica, vol. 122, pp. 569-576, 1990.
Palmieri, G.M.A., J. Bone and Mineral Research, vol. 7, Sup. 1, (Abs. 591) p. S240, 1992.
Koberstein, B., et al., Z. Gastroenterol, vol. 28, pp. 295-301, 1990.
Christensen, C., Acta Chir Scand., vol. 155, pp. 541-543, 1989.
Laron, Z., Israel J. Med. Sci., vol. 26, pp. 1-2, 1990.
Wilson, D., et al., Irish J. of Med. Sci., vol. 158, No. 1, pp. 31-32, 1989.
Micic, D., et al., Digestion, vol. 16, Sup. 1, p. 70, Abs. 193, 1990.
Mozell, E., et al., Surg., Gyn. & Obstetrics, vol. 170, pp. 476-484, 1990.
Cello, J.P., et al., Gastroenterol., vol. 98, No. 5 Pt.2, p. A163, 1990.
Alhindawi, R., et al., Canada J. Surg., vol. 33, No. 2, pp. 139-142, 1990.
Bianco, J. A., et al., Transplantation, vol. 49, No. 6, pp. 1194-1195, 1990.
O'Donnell, L.J.D., et al., Aliment. Pharmacol. Therap., vol. 4, No. 2, pp. 177-181, 1990.
Tulassay, Z., et al., Gastroenterology vol. 98, No. 5, Part 2, p. A238, 1990.
Fedorak, R.N., et al., Canada J. Gastroenterol, vol. 3, No. 2, pp. 53-57, 1989.
Modigliani, E., et al., Annales d'Endocrinologie, vol. 50, p. 483-488, 1989.
Camisa, C., et al., Cleveland Clinic J. Medicine, vol. 57, No. 1, pp. 71-76, 1990.
Hoeldtke, R.D., et al., Arch Phys Med Rehabil., vol. 69, pp. 895-898, 1988.
Kooner, J.S., et al., Proceedings of the Brit J. Clin. Pharm., vol. 28, pp. 735P-736P, Jul. 12-14, 1989.
Abelson, J.L., et al., J. Clinical Psychopharmacol, vol. 10, No. 2, pp. 128-132. 1990.
Soudah, H., et al., Clin. Research, vol. 39, No. 2, p. 303A, 1991.
Nott, D.M., et al., Brit. J. Surg., vol. 77, p. A691, 1990.
Branch, M.S., Gastroenterol, vol. 100, No. 5 Pt. 2, p. A425, 1991.
Chang, T.C.,et al., Brit Med Journ, vol. 304, p. 158, 1992.
Prelevic, G.M., et al., Metabolism, vol. 41, No. 9, Sup. 2, pp. 76-79, 1992.
Jenkins, S.A., et al., Gut, vol. 33, pp. 404-407, 1992.
Arrigoni, A., et al., Amer. Journal Gastroenterol, vol. 87, p. 1311, abs. 275, 1992.
Hartley, J.E., et al., Journal Royal Soc. Med., vol. 85, pp. 107-108.
Koper, J.W., et al., Journal of Clinical Endo. and Metabolism, vol. 74, No. 3, pp. 543-547, 1992.
Bartlett, D.L., et al., Surgical Forum (Amer. Coll. Surg.), vol. 42, pp. 14-16, 1991.
Hasler, W., et al., Gastroenterol., vol. 100, No. 5 Pt.2, p. A428, 1991.
Soudah, H., et al., Gastroenterol., vol. 98, No. 5 Pt. 2, Suppl. A129, 1990.
Bauer, W., Europ J. Pharmacol, vol. 183, p. 55, 1990.
Petrelli, N., et al., Proc. Amer. Soc. Clin. Oncol., vol. 10, p. 138, 1991.
Miller, D., et al., Can Med Assoc J, 1991, vol. 145, No. 3, pp. 227-228.
Mosdell et al., "Emerging indications for ocreotide therapy, part 1,"Am. J. Hosp. Pharm.,vol. 51, No. 9, 1994, pp. 1184-1192.
Mottet, et al., "Hemodynamic Effects of the Somatostatin Analog . . . Echo-Doppler Study," Hepatolgy, vol. 27, No. 4, 1998, pp. 920-925.
Ono et al., "Effects of Ocreotide Acetate Treatment for Scleroderma Bowel," Medical Journal, vol. 22, No. 4, 1996, pp. 233-237.
Pavolovic et al.,"Regression of Sclerodermatous Skin Lesions in a Patient with Carcinoid Syndrome Treated by Octreotide," Archives of Dermatology,vol. 41, No. 2, pp. 1207-1209.
Sobhani et al.,"Lanreotide inhibits human jejunal secretion induced by prostaglandin E1 in healthy volunteers," British Journal of Clinical Pharmacology,vol. 41, No. 2, 1996, pp. 109-114.
Wecbecker et al.,"Somatostatin Analogs for Diagnosis and Treatment of Cancer," Phamacology and Therapeutics vol. 60, No. 2, 1994, pp. 245-264.
Woltering et al., "Detection of occult gastrinomas with iodine 125 labeled lanreotide and intraoperative gamma detection," Surgeryvol. 116, No.6, 1994, pp. 1139-1147.
Biomeasure Inc.
Conway John D.
Henley III Raymond
Morrill Brian R.
LandOfFree
Methods of using a somatostatin analogue does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using a somatostatin analogue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using a somatostatin analogue will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1257200